neostigmine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 2 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zaleska, B | 1 |
| Aquilonius, SM | 1 |
| Sjöström, R | 1 |
1 review available for neostigmine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
[Progress in the treatment of degenerative diseases of the nervous system. Selected problems].
Topics: Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Humans; Huntington Disease; Lithium; Neostigmin | 1980 |
1 other study available for neostigmine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Cholinergic and dopaminergic mechanisms in Huntington's chorea.
Topics: Acetylcholine; Adult; Blood Pressure; Dopamine; Female; Heart Rate; Humans; Huntington Disease; Male | 1971 |